Published in Obesity and Diabetes Week, February 27th, 2006
The company reported sales of insulin analogs increased by 62%, sales of NovoSeven increased by 16%, sales in North America increased by 27% and sales in international operations increased by 25%.
Operating profit increased by 16% to US$1,349 million while underlying operating profit (measured in local currencies and excluding nonrecurring items) increased by around 20%. Net profit increased by 17% to US$978 million and earnings per share (diluted) increased by 20% to US$2.97.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.